Literature DB >> 12902847

Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Carlton W Thomas1, Philip W Lowry, Curtis L Franklin, Amy L Weaver, Gennett M Myhre, Dennis C Mays, William J Tremaine, James J Lipsky, William J Sandborn.   

Abstract

Mean corpuscular volume may correlate with erythrocyte 6-thioguanine nucleotide concentrations in patients treated with azathioprine and 6-mercaptourine. We conducted a study of 166 patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine to determine the relationship between mean corpuscular volume and erythrocyte 6-thioguanine nucleotide concentrations, disease activity as measured by the Inflammatory Bowel Disease Questionnaire (active disease <170, remission >170), and leukopenia. Blood was submitted for mean corpuscular volume, whole blood 6-thioguanine nucleotide concentration, and leukocyte count. The mean +/- SD mean corpuscular volume during treatment was 94.7 +/- 6.6 fL and the mean +/- SD change in mean corpuscular volume was 7.5 +/- 6.3 fL. There were significant correlations between mean corpuscular volume and erythrocyte 6-thioguanine nucleotide concentration (r(s) = 0.33, p < 0.001) and between change from baseline in mean corpuscular volume and erythrocyte 6-thioguanine nucleotide concentration (r(s) = 0.26, p = 0.001). There was no correlation between Inflammatory Bowel Disease Questionnaire scores and mean corpuscular volume values (r(s) = 0.01, p = 0.94). The mean corpuscular volume values in 55 patients with active disease and 111 patients in remission were similar (95.1 vs. 94.5 fL, p = 0.57). There was a weak negative correlation between the mean corpuscular volume and the leukocyte count, (r(s) = -0.18, p = 0.022). In patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine, mean corpuscular volume and change from baseline in mean corpuscular volume correlated with erythrocyte 6-thioguanine nucleotide concentrations and negatively with leukocyte counts, but did not correlate with disease activity as measured by the Inflammatory Bowel Disease Questionnaire. Measurement of mean corpuscular volume is a simple and inexpensive alternative to measurement of 6-thioguanine nucleotide concentrations in patients treated with azathioprine or 6-mercaptopurine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902847     DOI: 10.1097/00054725-200307000-00004

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

Review 1.  How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Authors:  Mark G Ward; Peter M Irving; Miles P Sparrow
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 2.  Megaloblastic anemia and other causes of macrocytosis.

Authors:  Florence Aslinia; Joseph J Mazza; Steven H Yale
Journal:  Clin Med Res       Date:  2006-09

3.  Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.

Authors:  Uri Kopylov; Robert Battat; Amine Benmassaoud; Laurence Paradis-Surprenant; Ernest G Seidman
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

4.  Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?

Authors:  Sven Frick; Daniel Müller; Gerd A Kullak-Ublick; Alexander Jetter
Journal:  Eur J Clin Pharmacol       Date:  2019-01-04       Impact factor: 2.953

5.  Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprine.

Authors:  Sherman Soman; Dhandapani Ashok; Sally A Connolly; Samantha J Cordell; Chris J Taylor; David I Campbell
Journal:  Drugs R D       Date:  2010

Review 6.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

7.  Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.

Authors:  Devaraj Jayachandran; Ann E Rundell; Robert E Hannemann; Terry A Vik; Doraiswami Ramkrishna
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

8.  A structural equation model to assess the pathways of body adiposity and inflammation status on dysmetabolic biomarkers via red cell distribution width and mean corpuscular volume: a cross-sectional study in overweight and obese subjects.

Authors:  Mariangela Rondanelli; Simone Perna; Tariq A Alalwan; Roberta Cazzola; Clara Gasparri; Vittoria Infantino; Federica Perdoni; Giancarlo Iannello; Daniele Pepe; Davide Guido
Journal:  Lipids Health Dis       Date:  2020-06-26       Impact factor: 3.876

9.  Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.

Authors:  Craig Mowat; Ian Arnott; Aiden Cahill; Malcolm Smith; Tariq Ahmad; Sreedhar Subramanian; Simon Travis; John Morris; John Hamlin; Anjan Dhar; Chuka Nwokolo; Cathryn Edwards; Tom Creed; Stuart Bloom; Mohamed Yousif; Linzi Thomas; Simon Campbell; Stephen J Lewis; Shaji Sebastian; Sandip Sen; Simon Lal; Chris Hawkey; Charles Murray; Fraser Cummings; Jason Goh; James O Lindsay; Naila Arebi; Lindsay Potts; Aileen J McKinley; John M Thomson; John A Todd; Mhairi Collie; Malcolm G Dunlop; Ashley Mowat; Daniel R Gaya; Jack Winter; Graham D Naismith; Holly Ennis; Catriona Keerie; Steff Lewis; Robin J Prescott; Nicholas A Kennedy; Jack Satsangi
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-08-30

Review 10.  Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease.

Authors:  Jack S Cornish; Elisa Wirthgen; Jan Däbritz
Journal:  Front Med (Lausanne)       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.